Drugs for rare diseases: Common list of drugs

The common list of new drugs ensures that the National Strategy for Drugs for Rare Diseases delivers the most possible benefits to all patients with rare diseases.

We will publish the names of drugs on the common list as the pan-Canadian Pharmaceutical Alliance concludes its price negotiations. We will also add information on which drugs each province and territory has elected to make available to their residents under bilateral agreements.

Common list of drugs

Currently, the publicly announced drugs on the common list are:

• Poteligeo (Mycosis fungoides or Sézary syndrome)
• Oxlumo (Primary hyperoxaluria type 1)
• Epkinly (Relapsed or refractory diffuse large B-cell lymphoma)
• Welireg (Von Hippel-Lindau disease)
• Yescarta (Follicular lymphoma; 2nd line treatment of diffuse large B-cell lymphoma or high-grade large B-cell lymphoma)

Note: The targeted disease state is provided for information. However, each drug has a detailed and specific Health Canada approved indication, which can be found in the Drug Product Database.

Elected drugs on the common list, by province or territory

British Columbia (agreement signed July 23, 2024)

• Poteligeo (Mycosis fungoides or Sézary syndrome)
• Oxlumo (Primary hyperoxaluria type 1)
• Epkinly (Relapsed or refractory diffuse large B-cell lymphoma)
• Welireg (Von Hippel-Lindau disease)
• Yescarta (Follicular lymphoma; 2nd line treatment of diffuse large B-cell lymphoma or high-grade large B-cell lymphoma)

Newfoundland and Labrador (agreement signed November 15, 2024)

• Poteligeo (Mycosis fungoides or Sézary syndrome)
• Oxlumo (Primary hyperoxaluria type 1)

Alberta (agreement signed Dec 5, 2024)

• Poteligeo (Mycosis fungoides or Sézary syndrome)
• Oxlumo (Primary hyperoxaluria type 1)
• Epkinly (Relapsed or refractory diffuse large B-cell lymphoma)